The effect of isosorbide mononitrate and frusemide on heart's function after major heart attack.
Phase 2
Not yet recruiting
- Conditions
- ST-segment elevation myocardial infarction (STEMI)
- Registration Number
- ACTRN12618000096257
- Lead Sponsor
- The Heart foundation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 92
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie isosorbide mononitrate and frusemide's impact on myocardial infarction outcomes?
How does isosorbide mononitrate and frusemide compare to standard STEMI treatments in reducing infarct size and mortality?
Which biomarkers correlate with improved cardiac function in STEMI patients treated with isosorbide mononitrate and frusemide?
What are the potential adverse events associated with isosorbide mononitrate and frusemide in acute myocardial infarction?
Are there alternative diuretic-nitrate combinations for STEMI management with better therapeutic profiles?